Abstract:Abstract Deregulation of ribosomal subunit levels and accessibility are hallmarks of cancer. Eukaryotic translation initiation factor 6 (eIF6) is a key regulator of ribosomal subunit association that is over expressed in many cancers including lung, colon, ovarian and breast cancers, and deregulation of eIF6 is correlated with a poor cancer prognosis. Association of eIF6 with 60S is critical for 60S assembly. However, eIF6 must be released from 60S prior to translation to permit inter subunit interactions between 60S and 40S and to facilitate the formation of translationally proficient 80S monosome. Release of eIF6 is deregulated in the ribosomopathy- Shwachman Diamond Syndrome that is predisposed to leukemias. Also, loss of eIF6 markedly delays tumorigenesis without affecting normal growth, which presents eIF6 as a viable therapeutic target. A potential therapeutic strategy is to target the eIF6 and 60S ribosomal interaction interface. Through biophysical analyses we had identified residues that are critical for the interaction between eIF6 and 60S ribosomal subunit. We show that targeting these key residues in the eIF6-60S interaction interface markedly delays colonic cancer growth and inhibits protein synthesis. Furthermore, we show that the levels of other eIFs and the release factors: SBDS, and EFL1-GTPase are unaltered in the mutant cells suggesting that the translational inhibition is primarily attributed to the deregulation of eIF6. Interestingly, targeting eIF6 leads to an upregulation of p53 independent of the DNA damage response, suggesting that ribosomal stress contributes to the stabilization of p53. Previously, it was shown that translation of Cdc42 was upregulated by eIF6 to promote invasiveness. However, Cdc42 levels were unaltered in the mutant cells. Future studies will determine the mRNA substrates that are translationally deregulated in the mutants. We will also determine the effect of disrupting eIF6 function in inhibiting tumor growth and progression in vivo. Category: MCB, Subcategory: MCB07-Gene regulation sub classification: Translational Control Citation Format: Kavya Meena Harish, Poonam Roshan, Aparna Biswas, Stella Anagnos, Riley Luebbers, Sofia Origanti. Targeting eIF6 to modulate ribosomal subunit association dynamics in cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7078.

Relaxed Initiation Pausing of Ribosomes Drives Oncogenic Translation

O-GlcNAcylation of Core Components of the Translation Initiation Machinery Regulates Protein Synthesis.

The Regulation of Protein Translation and Its Implications for Cancer

Translation from unconventional 5′ start sites drives tumour initiation

Eukaryotic translation initiation factors and cancer.

mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3 IBTK -mediated ubiquitination of eIF4A1 in cancer cells

mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3 -mediated non-degradative ubiquitination of eIF4A1

Mtorc1/s6k1 Signaling Promotes Sustained Oncogenic Translation Through Modulating CRL3IBTK-mediated Non-Degradative Ubiquitination of Eif4a1

Translation acrobatics: how cancer cells exploit alternate modes of translational initiation

Tight Coordination of Protein Translation and Hsf1 Activation Supports the Anabolic Malignant State

mRNA circularization by METTL3–eIF3h enhances translation and promotes oncogenesis

Functional screen for mediators of onco-mRNA translation specificity

Translational Regulation by eIFs and RNA Modifications in Cancer

Abstract 7078: Targeting eIF6 to modulate ribosomal subunit association dynamics in cancers

Non-canonical translation in cancer: significance and therapeutic potential of non-canonical ORFs, m6A-modification, and circular RNAs

Coordinate Regulation of Ribosome and tRNA Biogenesis Controls Hypoxic Injury and Translation

Suppression of Ribosomal Pausing by Eif5a is Necessary to Maintain the Fidelity of Start Codon Selection.

Impairing the production of ribosomal RNA activates mammalian target of rapamycin complex 1 signalling and downstream translation factors

Ribosome 18S m6A Methyltransferase METTL5 Promotes Translation Initiation and Breast Cancer Cell Growth

Ribosome ADP-ribosylation inhibits translation and maintains proteostasis in cancers

Prmt1-Mediated Translation Regulation Is A Crucial Vulnerability Of Cancer